Ore Pharmaceutical Holdings Inc.

Completing an initial public offering ought to be a big step in company development. It is a departure from a cosseted, insulated environment of unique technical approaches and regulatory progress and

The US commercial drug development company Ore Pharmaceuticals has named Mark Gabrielson president and chief executive officer. He succeeds Charles Dimmler. Mr Gabrielson serves on the company's board

The repositioning of drugs for new clinical indications is becoming an increasingly prominent development strategy because it can reduce development risk as well as both the time and investment requir

SimuGen Ltd. Innovative predictive liver toxicity testing 2 Oakington Business Park Cambridge, CB4 5DQ, UK Phone: +44 (0)870 220 5910 Fax: +44 (0)870 220 5910 Web Site: www.simugen.co.uk Contact: Quin